Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma.

Eur J Nucl Med Mol Imaging

PET Imaging Centre, St Thomas' Hospital, Lambeth Palace Road, London, SE1 7EH, UK.

Published: February 2009

Purpose: Error and variation in reporting remains one of the weakest features of clinical imaging despite enormous technological advances in nuclear medicine and radiology. The aim of this study was to evaluate agreement amongst experienced readers in staging non-small-cell lung cancer (NSCLC) with PET-CT.

Methods: A series of (18)F-FDG PET-CT scans from 100 consecutive patients were reviewed independently by three experienced readers, with two readers reviewing each scan series a second time. Individual mediastinal lymph node stations were assessed as benign/inflammatory, equivocal or malignant, and AJCC N and M stage were also assigned. Kappa (kappa) was used to compare ratings from two categories and weighted kappa (kappa(w)) for three or more categories, and kappa values were interpreted according to the Landis-Koch benchmarks.

Results: Both intra- and interobserver agreement for N and M staging were high. For M staging there was almost perfect intra- and interobserver agreement (kappa = 0.90-0.93). For N staging, agreement was either almost perfect or substantial (intraobserver kappa(w) = 0.79, 0.91; interobserver kappa(w) = 0.75-0.81). Importantly, there was almost perfect agreement for N0/1 vs N2/3 disease (kappa = 0.80-0.97). Agreement for inferior and superior mediastinal nodes (stations 1, 2, 3, 7, 8, 9) was either almost perfect or substantial (kappa(w) = 0.71-0.88), but lower for hilar nodes (10; kappa(w) = 0.56-0.71). Interreporter variability was greatest for aortopulmonary nodes (5, 6; kappa(w) = 0.48-0.55).

Conclusion: Amongst experienced reporters in a single centre, there was a very high level of agreement for both mediastinal nodal stage and detection of distant metastases with PET-CT. This supports the use of PET-CT as a robust imaging modality for staging NSCLC.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-008-0946-3DOI Listing

Publication Analysis

Top Keywords

staging non-small-cell
8
non-small-cell lung
8
experienced readers
8
intra- interobserver
8
interobserver agreement
8
perfect substantial
8
nodes kappaw
8
agreement
7
staging
6
kappa
6

Similar Publications

Introduction: Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Despite advancements in early detection and treatment, postsurgical recurrence remains a significant challenge, occurring in 30%-55% of patients within 5 years after surgery. This review analysed existing studies on the utilisation of artificial intelligence (AI), incorporating CT, PET, and clinical data, for predicting recurrence risk in early-stage NSCLCs.

View Article and Find Full Text PDF

Background: Prior research indicates a connection between immune-related adverse events (irAEs) and improved progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer. However, limited data exists for extensive stage small cell lung cancer (ES-SCLC).

Methods: This study included all ES-SCLC patients who received at least one dose of an immune checkpoint inhibitor between 2 January 2011 and 4 July 2022 using a large retrospective registry from a single institution.

View Article and Find Full Text PDF

Background: Non-small cell lung cancer (NSCLC) predominantly affects older adults; these patients have significant comorbidities, making them unsuitable for chemotherapy. This study aimed to evaluate the efficacy and safety of immune checkpoint inhibitor (ICI) along with anlotinib combination therapy as a first-line treatment in older NSCLC patients with programmed death ligand-1(PD-L1) expression<50%.

Methods: We conducted a retrospective observational study including 73 patients with advanced NSCLC treated at Nanjing Brain Hospital.

View Article and Find Full Text PDF

Background: No study has directly compared the outcomes of surgery and concurrent chemoradiotherapy (cCRT) in patients with stage III non-small cell lung cancer (NSCLC) to date. This study aimed to compare the treatment efficacy of complete resection and definitive cCRT.

Methods: Patients were recruited in this retrospective study from Yokohama Municipal Citizens' Hospital between January 2013 and December 2022.

View Article and Find Full Text PDF

The Comorbidity of Lung Cancer and ILD: A Review.

Pneumologie

January 2025

Klinik für Pneumologie, Kardiologie, internistische Intensivmedizin, Florence-Nightingale-Krankenhaus, Düsseldorf, Germany.

Patients with interstitial lung disease (ILD) and especially with idiopathic pulmonary fibrosis(IPF) suffer from reduced survival expectation and risk of exacerbations. Lung cancer is a relevant comorbidity in ILD patients and associated with impaired survival.The most frequent ILD among patients with NSCLC (Non-small cell lung cancer) is idiopathic pulmonary fibrosis (IPF), which is associated with an greater decline in lung function and a higher risk of death.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!